

MDDS Administration

Admission Criteria

MDDS is targeted for industry (pharma and biotech), service industry, academic, investment and government decision – and policy-makers who will benefit from a more in-depth, comprehensive and systematic training of the drug development value chain.

Applicants must have a higher University degree – such as MD, PhD or Graduate in Life Sciences – and a primary interest in medical product discovery, development, regulation, business development and marketing; at least 2 years of working experience is also requested.

Registration via [www](http://www.ecpm.ch) or mail (see below!)

A limited number of 20 postgraduate Master Students can be accepted (first come, first served); registration at the University Basel.

This first MDDS-Programme 2007 starts September 2007 and can be completed within 2-4 year, incl. Master Thesis.

Tuition Fees

C 1-6 Core Modules ECPM Course:
30 ECTS = CHF 11'500 (over 2 years)

C 3-16 Core Modules complementary and Master Thesis:
24 ECTS = CHF 17'500, incl. Examinations (over 2-4 years)

E 21+ Elective Modules:
6 ECTS minimally, they have to be obtained at own cost, anywhere in Europe at Bologna-accredited Courses

Individual Modules can be applied for à la carte, if space available.

Facility

Most Core Modules will take place at Basel University Pharmacenter. A few Modules will be at University Berne, University Lausanne and ETH Zürich. The Pharmacenter is on the University Basel Life Sciences Campus in the Center of the City and can easily be reached by road, rail or air (EuroAirport).


Contact

ECPM Executive Office
Prof. Dr. med. Dr. h.c. Fritz R. Bühler
Prof. Dr. med. Thomas D. Szucs
Dr. sc.nat. Annette Mollet
Dr. phil II Susanne Daniel
Amanda de Sola Pinto
Gisela Gautschi

University Hospital
CH-4031 Basel
Tel +41 61 265 7650


Fax +41 61 265 7655
ecpm@unibas.ch
www.ecpm.ch
Basler Kantonalbank
Account No. 16.572.653.50

First Announcement MDDS piloting E+T of IMI



On the ECPM Training Platform

Master of Advanced Studies in Drug Development Sciences MDDS



MDDS Collaborative Institutions



Center for
Economics and
Business
Management,
WWZ

SSEP
Swiss Society of
Experimental
Pharmacology





**Inaugurates the new
Master of Advanced Studies (MAS)
in Drug Development Sciences,**

MDDS

Programme 2007/2008

Certified by the
University of Basel
Advanced Study Center
Held at Pharmacenter Basel

The MDDS Portrait

The new Master of Advanced Studies in Drug Development Sciences, MDDS, Programme builds on and extends the ECPM Course Programme (which in the last 17 years i.e. 8 Course Cycles over 2 years each has trained more than 1200 integrated drug developers, the 9th Cycle with 160 participants will be started September 3, 2007.

The MDDS Programme is designed to:

- Develop a foundation of integrated knowledge in science-based medical product research and development and regulation within most disease biology areas.
- Address real world challenges encountered during the development, manufacture, review and commercialisation of a medicinal product.
- Understand future directions in global pharmaceutical and health economics and business environments, and their implications for product development and evaluation.
- Provide University, regulatory and industry professionals with a platform and network for the discussion of central issues concerning medicines development and new therapies.
- Obtain a Master of Advanced Studies (MAS) in Drug Development Sciences at the University Basel both for physicians as well as all other pharmaceutical professionals concerned with the entire medicines life cycle – from molecule to market place.

Training Concept

Intensive Modules of 1-4 days each with preparational work and interactive long-distance learning (i-learning), compatible with additional job commitment. English language only. The MDDS is recognised by the University Basel, Advanced Study Center, accredited Europe wide through the Bologna Title System and – as one of the European Master programmes – will be coordinated and quality assured by IFAPP's new EFCPM, European Federation of Courses in Pharmaceutical Medicine, as well as the EUFEPS Training Platform, eventually by the EMRA, European Medicines Research Academy, created as a consequence of the IMI, Innovative Medicines Initiative which is owned by the European Commission together with EFPIA, European Federation of Pharmaceutical Industry Association.

Diploma Examination

In addition to the ECPM Course triple examination there will be an assessment after each Module according to the Bologna System.

Master Thesis

A Master Thesis (ca. 30 pages) will be requested on the basis of (practical) scientific work under the supervision of a coach at University or in industry.

Faculty

In addition to the ca. 130 ECPM Course Faculty there will be another ca. 40 experts from University, industry and regulatory institutions and from Europe and world-wide.

9.8.07

C13 Pharmacoepidemiology
(co-organised with DIA Europe) 3.-4.12.07

Base Modules = ECPM Course

= 30 ECTS

B1	Global Drug Development and Pharmaceutical Business Environment	3.-6.9.2007
B2	From Preclinical (Safety and Efficacy) Testing to Proof of Concept in Humans	28.-31.1.2008
B3	Learning and Confirming Trials: Finding and Confirming the Right Dose	30.6.-3.7.2008
B4	Confirming Trials: Methodology and Biostatistics	8.-11.9.2008
B5	Global Registration and Approval Process	2.-5.2.2009
B6	Integrated Product Development, Safety, Portfolio Management and Marketing	8.-11.6.2009

Complementary Modules

= 16 ECTS

C7	Pathophysiology-Based Pharmacology and Safety (co-organised with SSEP)	23.-25.4.08 21.-23.5.08 23.-25.6.08
C8	Preclinical Drug Development: Focus on ADME and Safety, PK/PD, Simulation and Modelling	.3.08
C9	Pharmaceutical Development, Technologies and Production (organised by ETH Zürich)	
C10	Quality Assurance and Quality Management (organised by ETH Zürich)	
C11	Drug Safety and Pharmacovigilance	
C12	Practice of Clinical Trials and Regulations (GCP) (co-organised with PFC)	

D14	Health Economics	
D15	European Course for Life Sciences Executives Leadership	6.-8.3.2008 17.-19.4.2008
D16	European Course for BioBusiness Development	25.-28.6.2008
Thesis	Master Thesis = 8 ECTS	

Elective Modules + CPD

= 6 ECTS

ECPM Platform 	E21	Frontiers in Drug Development
	E22	ECPM interactive E-learning
	E23	Disease Area Internships
	E24	Scientific Communication
	E25	Scientific Medical Writing
	E26	Principles of Marketing Management
	E27	Bioethics
	E28	Partnered Programmes in Washington DC, San Francisco, Tokyo and Beijing
	E+	

Collaborative
Network



- E31** Medicinal Chemistry
- E32** Electives at PharmaCenter, Basel and other Universities
- E33** Additional Electives by EUFEPS
- E34** Additional Electives by IFAPP
- E35** Additional Electives by DIA Europe
- E+**
 - Clinical Study Management
 - Excellence in Pharmacology
 - Risk Management